Premium
Anti‐Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer
Author(s) -
Wang Deg,
Dafik Laila,
Nolley Rosalie,
Huang Wei,
Wolfinger Russell D.,
Wang LaiXi,
Peehl Donna M.
Publication year - 2013
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21063
Subject(s) - prostate cancer , prostatectomy , cancer , medicine , antibody , biomarker , prostate , prostate specific antigen , oncology , antigen , cancer biomarkers , pca3 , serology , immunology , biology , biochemistry
AbstractPreclinical ResearchThis study bridges a carbohydrate microarray discovery and a large‐scale serological validation of anti‐oligomannose antibodies as novel serum biomarkers of aggressive prostate cancer ( PCa ). Experimentally, a M an9‐cluster‐specific enzyme‐linked immunosorbent assay was established to enable sensitive detection of anti‐ M an9 antibodies in human sera. A large‐cohort of men with PCa or benign prostatic hyperplasia ( BPH ) whose sera were banked at S tanford U niversity was characterized using this assay. Subjects included patients with 100% G leason grade 3 cancer ( n = 84), with G leason grades 4 and/or 5 cancer ( n = 204), and BPH controls ( n = 135). Radical prostatectomy G leason grades and biochemical ( PSA ) recurrence served as key parameters for serum biomarker evaluation. It was found that IgG Man9 and IgM Man9 were widely present in the sera of men with BPH , as well as those with cancer. However, these antibody reactivities were significantly increased in the subjects with the largest volumes of high grade cancer. Detection of serum IgG Man9 and IgM Man9 significantly predicted the clinical outcome of PCa post‐radical prostatectomy. Given these results, we suggest that IgG Man9 and IgM Man9 are novel serum biomarkers for monitoring aggressive progression of PCa . The potential of oligomannosyl antigens as targets for PCa subtyping and targeted immunotherapy is yet to be explored.